AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 172 min read$KMTS

Webster Brian Daniel sold $337K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.44 ($22.01–$24.00, $0.34M total) across 3 trades on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Jul 17, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; there is no new company fundamental catalyst in the text.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 designation typically limits interpretive value.

03

What to watch

The filing does not state whether additional insider sales occurred around the same period, nor does it provide post-sale performance or any new operational catalyst.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-17 for a 2026-07-15 insider sale.

Background

This is an SEC Form 4 insider transaction for Kestera Medical Technologies, Ltd. (KMTS) by an officer/director.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Webster Brian Daniel sold $336,609 of KMTS shares via an open-market sale under a pre-arranged 10b5-1 plan on 2026-07-15.

Expected impact

Likely limited near-term impact; any reaction should be muted because the sale is pre-arranged and the article provides no new fundamentals.

Evidence & confidence

Form 4 shows a scheduled open-market sale (Code S) with a stated 10b5-1 plan, and no accompanying company-specific news (earnings, guidance, contracts, litigation) is included.

Market effects

Sector

No sector read-through; this is a single-company insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so traders may ignore it.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Webster Brian Daniel

    Officer and director who sold shares under an open-market sale (10b5-1 plan).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min